To Cite:
Zheng
Y, Zhang
S, Tan Grahn
H M, Ye
C, Gong
Z, et al. Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis,
Hepat Mon.
2013
;13(4):e6496.
doi: 10.5812/hepatmon.6496.
1.
Galbraith RM, Williams R, Eddleston ALWF, Zuckerman AJ, Bagshawe KD. fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975; 306(7934): 528-30[DOI]
2.
Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975; 68(1): 105-12[PubMed]
3.
Bird GL, Smith H, Portmann B, Alexander GJ, Williams R. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med. 1989; 73(270): 895-902[PubMed]
4.
Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol Oncol. 1990; 8(5): 261-70[PubMed]
5.
Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100(1): 182-8[PubMed]
6.
Soh LT, Ang PT, Sng I, Chua EJ, Ong YW. Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer. 1992; 28(8–9): 1338-9[DOI]
7.
Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med. 1985; 145(7): 1313-4[PubMed]
8.
Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987-1991. Cancer. 1996; 78(10): 2210-5
9.
Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer. 1999; 81(1): 69-74[DOI][PubMed]
10.
Yeo W,
Chan PKS,
Zhong S,
Ho WM,
Steinberg JL,
Tam JS,
et al.
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62(3): 299-307
11.
Yeo W,
Hui EP,
Chan AT,
Ho WM,
Lam KC,
Chan PK,
et al.
Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol. 2005; 28(4): 379-84[PubMed]
12.
Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004; 24(6): 540-6[DOI][PubMed]
13.
Yeo W,
Chan PK,
Hui P,
Ho WM,
Lam KC,
Kwan WH,
et al.
Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003; 70(4): 553-61[DOI][PubMed]
14.
Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010; 25(5): 864-71[DOI][PubMed]
15.
Lau GK,
Yiu HH,
Fong DY,
Cheng HC,
Au WY,
Lai LS,
et al.
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125(6): 1742-9[PubMed]
16.
Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma. 2003; 44(5): 759-66[DOI][PubMed]
17.
Yeo W,
Chan PK,
Ho WM,
Zee B,
Lam KC,
Lei KI,
et al.
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004; 22(5): 927-34[DOI][PubMed]
18.
Persico M,
De Marino F,
Russo GD,
Morante A,
Rotoli B,
Torella R,
et al.
Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood. 2002; 99(2): 724-5[PubMed]
19.
Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002; 100(2): 391-6[PubMed]
20.
Silvestri F,
Ermacora A,
Sperotto A,
Patriarca F,
Zaja F,
Damiani D,
et al.
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol. 2000; 108(2): 394-6[PubMed]
21.
Dai MS, Chao TY. Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive? Breast Cancer Res Treat. 2005; 92(1): 95-6[DOI][PubMed]
22.
Loomba R,
Rowley A,
Wesley R,
Liang TJ,
Hoofnagle JH,
Pucino F,
et al.
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008; 148(7): 519-28[PubMed]
23.
Yeo W,
Ho WM,
Hui P,
Chan PK,
Lam KC,
Lee JJ,
et al.
Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004; 88(3): 209-15[DOI][PubMed]
24.
Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006; 24(7): 1003-16[DOI][PubMed]
25.
Long M,
Jia W,
Li S,
Jin L,
Wu J,
Rao N,
et al.
A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat. 2011; 127(3): 705-12[DOI][PubMed]
26.
Yun J,
Kim KH,
Kang ES,
Gwak GY,
Choi MS,
Lee JE,
et al.
Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011; 104(4): 559-63[DOI][PubMed]
27.
Hsu C,
Hsiung CA,
Su IJ,
Hwang WS,
Wang MC,
Lin SF,
et al.
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008; 47(3): 844-53[DOI][PubMed]
28.
Li YH,
He YF,
Jiang WQ,
Wang FH,
Lin XB,
Zhang L,
et al.
Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006; 106(6): 1320-5[DOI][PubMed]
29.
Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol. 2001; 65(3): 473-7[PubMed]
30.
Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43(2): 209-20[DOI][PubMed]
31.
Nevens F,
Main J,
Honkoop P,
Tyrrell DL,
Barber J,
Sullivan MT,
et al.
Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology. 1997; 113(4): 1258-63[PubMed]
32.
Kao JH, Chen PJ, Lai MY, Chen DS. hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000; 118(3): 554-9
33.
Lau GK,
Leung YH,
Fong DY,
Au WY,
Kwong YL,
Lie A,
et al.
High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002; 99(7): 2324-30[PubMed]
34.
Liu CJ, Kao JH, Chen PJ, Lai MY, Chen DS. Molecular epidemiology of hepatitis B viral serotypes and genotypes in taiwan. J Biomed Sci. 2002; 9(2): 166-70[PubMed]
35.
Nishizono A,
Kohno K,
Takita-Sonoda Y,
Hiraga M,
Terao H,
Fujioka T,
et al.
Sequential analyses of the mutations in the core upstream and precore regions of hepatitis B virus genome in anti-HBe positive-carriers developing acute exacerbation. J Med Virol. 1997; 53(3): 266-72
36.
Steinberg JL,
Yeo W,
Zhong S,
Chan JY,
Tam JS,
Chan PK,
et al.
Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role. J Med Virol. 2000; 60(3): 249-55
37.
Yeo W,
Lam KC,
Zee B,
Chan PS,
Mo FK,
Ho WM,
et al.
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004; 15(11): 1661-6[DOI][PubMed]
38.
Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci. 1992; 37(8): 1253-9[PubMed]
39.
Yeo W,
Zee B,
Zhong S,
Chan PK,
Wong WL,
Ho WM,
et al.
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004; 90(7): 1306-11[DOI][PubMed]
40.
Chen CJ,
Yang HI,
Su J,
Jen CL,
You SL,
Lu SN,
et al.
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1): 65-73[DOI][PubMed]
41.
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3): 678-86[DOI][PubMed]
42.
Lau DT,
Khokhar MF,
Doo E,
Ghany MG,
Herion D,
Park Y,
et al.
Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000; 32(4 Pt 1): 828-34[DOI][PubMed]
43.
Okita R,
Takahashi M,
Narahara H,
Sanada Y,
Okada M,
Kawakami Y,
et al.
Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy. Clin J Gastroenterol. 2009; 2(3): 214-7[DOI]
44.
Ling R,
Mutimer D,
Ahmed M,
Boxall EH,
Elias E,
Dusheiko GM,
et al.
Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 1996; 24(3): 711-3[DOI][PubMed]
45.
Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother. 2001; 12 Suppl 1: 67-71[PubMed]
46.
Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2002; 17 Suppl 3-7[PubMed]
47.
Allen MI,
Deslauriers M,
Andrews CW,
Tipples GA,
Walters KA,
Tyrrell DL,
et al.
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998; 27(6): 1670-7[DOI][PubMed]
48.
Gilson RJ,
Chopra KB,
Newell AM,
Murray-Lyon IM,
Nelson MR,
Rice SJ,
et al.
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat. 1999; 6(5): 387-95[PubMed]
49.
Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology. 2004; 39(3): 857-61[DOI][PubMed]
50.
Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis. Cancer Invest. 2006; 24(5): 548-52[DOI][PubMed]
51.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2): 507-39[DOI][PubMed]
52.
de Man RA,
Wolters LM,
Nevens F,
Chua D,
Sherman M,
Lai CL,
et al.
Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology. 2001; 34(3): 578-82[DOI][PubMed]
53.
Farrell GC. Clinical potential of emerging new agents in hepatitis B. Drugs. 2000; 60(4): 701-10[PubMed]
54.
Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006; 4(9): 1076-81[DOI][PubMed]
55.
Mimura N,
Tsujimura H,
Ise M,
Sakai C,
Kojima H,
Fukai K,
et al.
[Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy]. Rinsho Ketsueki. 2009; 50(12): 1715-9[PubMed]
56.
Schildgen O, Hartmann H, Gerlich WH. Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication. Scand J Gastroenterol. 2006; 41(2): 245-6[DOI][PubMed]
57.
Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004; 83(12): 769-74[DOI][PubMed]
58.
Hui CK,
Cheung WW,
Au WY,
Lie AK,
Zhang HY,
Yueng YH,
et al.
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005; 54(11): 1597-603[DOI][PubMed]
59.
Idilman R. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut. 2006; 55(8): 1208-9[PubMed]
60.
Zhang HY, Liu ZG, Zhang Z, Gong HY. [Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy]. Zhonghua Zhong Liu Za Zhi. 2010; 32(6): 459-62[PubMed]